Non-Malignant Breast Disorders without CC/MCC DRG Reimbursement

DRG 601 encompasses inpatient stays for non-malignant breast disorders without Complication or Comorbidity or Major Complication or Comorbidity, covering benign breast conditions and uncomplicated postoperative care. Classification to this Diagnosis-Related Group matters because it sets the prospective payment category used by Medicare for hospital reimbursement and reflects lower expected resource intensity than cases with complications or malignancy.

DRG 601 Overview

DRG 601 covers inpatient admissions for non-malignant breast disorders without Complication or Comorbidity or Major Complication or Comorbidity and typically includes conditions such as benign breast masses, cysts, mastitis without systemic complication, and postoperative care following non-oncologic breast procedures. This Diagnosis-Related Group is used to classify cases with relatively low expected resource use compared with breast admissions that include complications or malignancy. For Medicare payment, assignment to DRG 601 affects the base prospective payment and grouping logic for hospitals billing the Centers for Medicare & Medicaid Services. Accurate clinical coding and documentation determine whether an admission is classified to this Diagnosis-Related Group and thus directly influences reimbursement pathways.

Prospective randomized trials comparing conservative management strategies (e.g., observation, analgesia, hormonal modulation) versus minimally invasive procedural interventions (such as ultrasound-guided aspiration or image-guided cyst drainage) for symptomatic non-malignant breast masses. These studies enroll adult women presenting acutely or electively with benign cysts, fibroadenomas, mastitis, or symptomatic breast pain to determine short-term symptom relief, need for repeat procedures, and complication rates. Results inform clinicians on which initial interventions reduce inpatient stays, lower complication-related costs, and optimize resource use for payers and hospital case management.
Comparative effectiveness studies of diagnostic pathways that evaluate imaging-first versus biopsy-first approaches in patients with suspicious but likely benign breast findings. These observational or pragmatic randomized studies focus on patients with ambiguous imaging (BI-RADS 3–4a scenarios), assessing downstream utilization including additional imaging, core needle biopsies, surgical excisions, length of stay when admitted, and rates of diagnostic certainty. Findings are relevant to providers and payers because they can reduce unnecessary procedures, avoid inpatient admissions for diagnostic workups, and align care with value-based reimbursement by minimizing low-yield resource use.
Post-discharge outcomes and care transitions research examining recurrence, readmission, patient-reported outcomes (pain, cosmetic satisfaction), and outpatient follow-up adherence after inpatient management for conditions like complicated mastitis, abscess drainage, or post-procedural complications. These cohort studies or registry analyses target the subpopulation requiring hospital-based care to identify predictors of readmission, outpatient resource needs (wound care, antibiotics), and costs over 30–90 days. Insights help hospitals and payers design discharge planning, outpatient support programs, and bundled payment models to reduce readmissions and total cost of care while maintaining quality for this DRG.

Prospective randomized trials comparing conservative management strategies (e.g., observation, analgesia, hormonal modulation) versus minimally invasive procedural interventions (such as ultrasound-guided aspiration or image-guided cyst drainage) for symptomatic non-malignant breast masses. These studies enroll adult women presenting acutely or electively with benign cysts, fibroadenomas, mastitis, or symptomatic breast pain to determine short-term symptom relief, need for repeat procedures, and complication rates. Results inform clinicians on which initial interventions reduce inpatient stays, lower complication-related costs, and optimize resource use for payers and hospital case management.
Comparative effectiveness studies of diagnostic pathways that evaluate imaging-first versus biopsy-first approaches in patients with suspicious but likely benign breast findings. These observational or pragmatic randomized studies focus on patients with ambiguous imaging (BI-RADS 3–4a scenarios), assessing downstream utilization including additional imaging, core needle biopsies, surgical excisions, length of stay when admitted, and rates of diagnostic certainty. Findings are relevant to providers and payers because they can reduce unnecessary procedures, avoid inpatient admissions for diagnostic workups, and align care with value-based reimbursement by minimizing low-yield resource use.
Post-discharge outcomes and care transitions research examining recurrence, readmission, patient-reported outcomes (pain, cosmetic satisfaction), and outpatient follow-up adherence after inpatient management for conditions like complicated mastitis, abscess drainage, or post-procedural complications. These cohort studies or registry analyses target the subpopulation requiring hospital-based care to identify predictors of readmission, outpatient resource needs (wound care, antibiotics), and costs over 30–90 days. Insights help hospitals and payers design discharge planning, outpatient support programs, and bundled payment models to reduce readmissions and total cost of care while maintaining quality for this DRG.

OpenPayer

Summary & Overview

Non-Malignant Breast Disorders without CC/MCC: Inpatient Reimbursement Overview

DRG 601 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes